Author

Jennifer Rivière

Technical University of MunichORCID 0000-0002-4680-2071Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Katharina S. S. GötzeiD· 2 shared Alexander Schäffer· 1 shared Ali AzhdariniaiD· 1 shared Angelique Schönefeld· 1 shared Ashley WesterbackiD· 1 shared Borhane GuezgueziD· 1 shared Catherine WölfeliD· 1 shared Christoph PlassiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Katharina S. S. GötzeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells

Nghia Trong Nguyen, Yu Min, Jennifer Rivière, Mark van der Garde, Sukhen C. Ghosh, Laura M. Bartos, Matthias Brendel, Florian C. Bassermann, Ali Azhdarinia, Wolfgang Weber, Katharina S. S. Götze, Susanne Kossatz

This paper shows that hematopoietic stem and progenitor cells express somatostatin receptors, leading to unexpected toxicity from radiopharmaceuticals used in neuroendocrine tumors.

Theranostics · May 25, 2025Peer-reviewedCancer Biology

DNMT/G9a Complex Inhibition Uncovers Epigenetic Vulnerabilities and Induces IFN-Response in Acute Myeloid Leukemia

Angelique Schönefeld, Costanza Zanetti, Eric C. Schmitt, Kevin Woods, Ashley Westerback, Sidney M. Mitsch, Frank Rühle, Simge Kelekçi, Lisa Fol, Viral Shah, Miriam Sanchez-Saez, Sophia Thevissen, Alexander Schäffer, Ulrike Regina Schmits, Daniel Sasca, , Borhane Guezguez

This study shows that inhibiting the DNMT/G9a complex targets specific epigenetic vulnerabilities in AML, inducing an IFN response and improving therapeutic outcomes.

bioRxiv · Dec 11, 2024 · PreprintCancer Biology